SCHEMBL102562

SCHEMBL102562

CC1(C)OB(c2ccc(O)cc2)OC1(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 13/20 0.59
LPL P06858 12/20 0.59
F11 P03951 2/20 0.51
CA1 P00915 3/20 0.49
CA2 P00918 3/20 0.49
CA9 Q16790 3/20 0.49
CA12 O43570 1/20 0.49
CA3 P07451 1/20 0.49
CA4 P22748 1/20 0.49
CA6 P23280 1/20 0.49
CA5A P35218 1/20 0.49
CA7 P43166 1/20 0.49
CA14 Q9ULX7 1/20 0.49
CA5B Q9Y2D0 1/20 0.49
P4HB P07237 1/20 0.45
F2 P00734 1/20 0.44
PRSS1 P07477 1/20 0.44
PRSS2 P07478 1/20 0.44
PRSS3 P35030 1/20 0.44
ESR2 Q92731 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4813824 0.94 LIPG (0.69) LIPGLPLF11CA1CA2
SCHEMBL23750301 0.94 LIPG (0.69) LIPGLPLF11CA1CA2
SCHEMBL14754517 0.89 CA1 (0.53) LIPGLPLF11CA1CA2
SCHEMBL15476363 0.89 P4HB (0.56) LIPGLPLF11CA1CA2
SCHEMBL19729193 0.89 LIPG (0.69) LIPGLPLF11CA1CA2
SCHEMBL15476364 0.89 P4HB (0.56) LIPGLPLF11CA1CA2
SCHEMBL19729194 0.89 LPL (0.49) LIPGLPLF11CA1CA2
SCHEMBL228212 0.88 LPL (0.71) LIPGLPLF11CA1CA2
SCHEMBL15481263 0.87 P4HB (0.48) LIPGLPLF11CA1CA2
SCHEMBL24094844 0.87 HTT (0.52) LIPGLPLF11CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1675 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES THE JOHNS HOPKINS UNIVERSTY 2023-07-06 US claimed
EP-4157998-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES The Johns Hopkins University (US) 2023-04-05 EP claimed
CN-114213768-A Modified multi-walled carbon nanotube/ethylene propylene diene monomer composite flame retardant material 雒慧星 2022-03-22 CN claimed
EP-3344232-B1 MICELLES FOR MUCOADHESIVE DRUG DELIVERY UNIV MCMASTER (CA) 2022-01-26 EP claimed
WO-2021036022-A1 PET/CT TRACER HAVING SELECTIVITY FOR DIFFERENT LUNG CANCER CELLS, PREPARATION METHOD THEREFOR AND USE THEREOF 四川大学华西医院 2021-03-04 WO claimed
CN-112156071-A Preparation method of responsive amphiphilic polymer self-assembled micelle 天津工业大学 2021-01-01 CN claimed
CN-110642861-B PET/CT tracer agent with selectivity on different lung cancer cells and preparation method and application thereof 四川大学华西医院 2021-01-01 CN claimed
US-10611908-B2 Micelles for mucoadhesive drug delivery MCMASTER UNIVERSITY (CA) 2020-04-07 US claimed
CN-110642861-A PET/CT tracer agent with selectivity on different lung cancer cells and preparation method and application thereof 四川大学华西医院 2020-01-03 CN claimed
US-20180265694-A1 Micelles for Mucoadhesive Drug Delivery MCMASTER UNIVERSITY (CA) 2018-09-20 US claimed
EP-1127060-B8 HYDROBORONATION PROCESS COMMW SCIENT IND RES ORG (AU) 2005-01-05 EP claimed
US-20040133028-A1 Hydroboronation process COMMONWEALTH SCIENTIFIC 2004-07-08 US claimed
US-6680401-B1 BORON COMPOUNDS SUCH AS 4-(METHOXYMETHYL)-1,3,2-DIOXABOROLANE, USED AS COUPLERS OR CHEMICAL INTERMEDIATES FOR DRUGS, PESTICIDES OR IN COMBINATORIAL CHEMISTRY COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2004-01-20 US claimed
EP-1127060-A4 HYDROBORONATION PROCESS COMMW SCIENT IND RES ORG (AU) 2002-08-21 EP claimed
EP-1127060-A1 HYDROBORONATION PROCESS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2001-08-29 EP claimed
WO-2000027853-A1 HYDROBORONATION PROCESS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2000-05-18 WO claimed
EP-4166557-B1 INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES NOVARTIS AG (CH) 2026-05-06 EP disclosed
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES UNIV YALE (US) 2026-04-30 US disclosed
EP-1127060-A1 HYDROBORONATION PROCESS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2001-08-29 EP disclosed
WO-2000027853-A1 HYDROBORONATION PROCESS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2000-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133028-A1 Hydroboronation process ALKBH3, HPD, HVCN1 LIPG 4522/4885LPL 4659/4885F11 2087/4885
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, VHL, ADRM1 LIPG 1464/4885LPL 1736/4885F11 2636/4885
US-20230210790-A1 GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES EPX, EPCAM, ELANE LIPG 25/4885LPL 606/4885F11 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.